Dental implant failures are rare events.
The contributory role of the patient's medical conditions and
medication(s) in dental implant failure is not fully understood. Drs.
Subramanian and Quek from Rutgers were interested in investigating
whether
anti-resorptive therapies (e.g.,
bisphosphonates)
contribute to dental implant failures. The survey questions were geared
towards identifying early and delayed implant failures in conjunction
with systemic conditions such as diabetes, diseases such as osteoporosis
and cancer that necessitated anti-resorptive therapy.
Implant failure was defined as 'implant mobility in rotational, axial or horizontal direction' in the presence/ absence of pain or discomfort and radiographic evidence of peri-implant bone loss.
Among 277 responders, 167 (nearly
60%) reported implant failures.Nearly a third of all implant failures
were observed in the setting of systemic conditions in the patients,
warranting a closer look at these entities. Anti-resorptive therapy has
been reported by nearly 10-15% of the responders as associated with
early and delayed dental implant failures. It was notable that over 120
of the nearly 170 responders who reported implant failures expressed
their willingness to be contacted for additional information, important
in order to build on this preliminary data. As the longevity of implants
in an Implant Registry Study is explored further in the network, the
results of this quick poll will help inform that workgroup.
Click here to view the table with the summary of results.
Comments